A look at earnings from the view of macro-economists and market technicians
A bottom-up view of earnings from professional equity analysts
Documentation, research, and support for the information provided
Sign in using:
Don't have an account?
Earnings Whisper ®
1st Quarter March 2021
Revenue: $361.08 Mil
6:00 AM ET
Wednesday, February 24, 2021
United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results
What do you expect when UTHR reports earnings?
Where is UTHR's stock price going from here?
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Merck & Co.
Johnson & Johnson